HC Wainwright Has Optimistic Outlook of AURA FY2024 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright raised their FY2024 earnings estimates for shares of Aura Biosciences in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. White now expects that the company will post earnings of ($1.69) per share for the year, up from their previous forecast of ($1.71). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2025 earnings at ($1.94) EPS and FY2026 earnings at ($2.06) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02.

AURA has been the subject of several other reports. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. JMP Securities increased their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Scotiabank lifted their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Finally, BTIG Research increased their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Trading Down 5.0 %

NASDAQ:AURA opened at $9.47 on Monday. The stock has a 50 day moving average of $9.82 and a two-hundred day moving average of $8.54. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The firm has a market cap of $473.03 million, a P/E ratio of -5.47 and a beta of 0.33.

Insiders Place Their Bets

In related news, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This represents a 5.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Los Pinos Elisabet De sold 9,200 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. The trade was a 2.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 67,259 shares of company stock worth $780,699 over the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Levin Capital Strategies L.P. raised its holdings in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Aura Biosciences by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the period. American International Group Inc. grew its position in Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares during the last quarter. Long Focus Capital Management LLC increased its stake in Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the period. Finally, Virtu Financial LLC acquired a new position in Aura Biosciences in the 1st quarter valued at $144,000. 96.75% of the stock is owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.